Axonyx completes phase 1 study of Posiphen for treatment of Alzheimer's disease

By Lisa Kerner

Erie, Pa., May 15 - Axonyx Inc. said it completed its second phase 1 study of Posiphen for the treatment of Alzheimer's disease progression.

One aim of the double-blind, placebo-controlled study was to establish well tolerated doses, according to a company news release.

In the study, Posiphen 20mg, 40 mg and 60mg was given four times daily, for a period of 7, 7 and 10 days respectively, except on the first and last day of each dosing period when one single dose of Posiphen was given.

In each cohort of 16 subjects, 12 received Posiphen and 4 who received placebo.

Detailed safety, pharmacokinetic and pharmacodynamic analyses are ongoing, Axonyx said.

Posiphen appears to modify the metabolism of beta-amyloid precursor protein (beta-APP) which form senile plaques found in Alzheimer's disease.

Axonyx Inc. is a biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.